Allarity Therapeutics, Inc.
ALLRAllarity Therapeutics is a clinical-stage precision medicine biotechnology company that develops oncology therapeutics paired with drug-specific companion diagnostics.
Table of contents
Earnings
Next report
Aug 21, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Allarity Therapeutics is a clinical-stage precision medicine biotechnology company that develops oncology therapeutics paired with drug-specific companion diagnostics. The company utilizes its proprietary Drug Response Predictor (DRP) platform to identify gene expression signatures that predict patient sensitivity to specific anti-cancer treatments. This approach aims to increase the probability of clinical success by selecting patient populations most likely to benefit from targeted therapies.
A pioneer in transcriptomic-based companion diagnostics with a validated platform used in over 35 clinical trials to predict drug response.
Questions, answered.
- What is Allarity Therapeutics, Inc.'s market cap?
- Allarity Therapeutics, Inc. (ALLR) has a market capitalization of $19.6M and trades on NASDAQ.
- Who are Allarity Therapeutics, Inc.'s competitors?
- Allarity Therapeutics, Inc.'s key competitors include Lantern Pharma, Bristol-Myers Squibb, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Allarity Therapeutics, Inc. partner with?
- Allarity Therapeutics, Inc.'s notable partners include Eisai Pharmaceuticals, Chosa Oncology, Smerud Medical Research International, and others.
- What subsidiaries does Allarity Therapeutics, Inc. have?
- Allarity Therapeutics, Inc.'s subsidiaries include Allarity Therapeutics A/S, Allarity Acquisition Subsidiary.
- Where is Allarity Therapeutics, Inc. headquartered?
- Allarity Therapeutics, Inc. is headquartered in United States of America and employs approximately 6 people. It has been publicly traded since 2021.